170867 ⎘
Detection or diagnosis of diseases; Cardiovascular disorders Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
INHIBITORS OF GALECTIN-3 AND METHODS OF USE THEREOF
#302Cardiomyocytes from induced pluripotent stem cells from patients and methods of use thereof
#303Diagnostic Methods for Assessing Risk of Chagas Disease and Heart Failure
#304NOVEL DESMIN PHOSPHORYLATION SITES USEFUL IN DIAGNOSIS AND INTERVENTION OF CARDIAC DISEASE
#305CARDIOVASCULAR AUTOIMMUNE DISEASE PANEL AND METHODS OF USING SAME
#306Methods for treatment with bucindolol based on genetic targeting
#307Means and methods for diagnosing heart failure in a subject
#308METHODS AND ASSAYS FOR RISK PREDICTION, DIAGNOSIS, AND ANALYSIS OF MYOCARDIAL INFARCTION, HEART FAILURE AND REDUCED CARDIAC FUNCTION
#309Methods predicting risk of an adverse clinical outcome
#310Means and Methods for Diagnosing and/or Treating a Subject at Risk of Developing Heart Failure
#311Biomarkers for sensitive detection of statin-induced muscle toxicity
#312MCAM as a biomarker for fluid homeostasis
#313METHODS OF PREDICTING AND TREATING ADVERSE CARDIAC EVENTS
#314FIBROSIS INHIBITOR
#315USE OF GALECTIN-3 FOR DETECTING AND PROGNOSING HEART FAILURE AFTER ACUTE CORONARY SYNDROME
#316METHOD FOR IDENTIFYING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE BY DETERMINING THE LEVEL OF GALECTIN-3 OR THROMBOSPONDIN-2
#317BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF ACUTE HEART FAILURE AND USES THEREOF
#318PON1 as a marker for heart failure
#319METHODS OF PROGNOSIS AND DIAGNOSIS IN CHRONIC HEART FAILURE
#320METHODS FOR PROTECTING DOPAMINERGIC NEURONS FROM STRESS AND PROMOTING PROLIFERATION AND DIFFERENTIATION OF OLIGODENDROCYTE PROGENITORS BY NRG-2
#321Use of GSTP1
#322Methods of Diagnosing Diastolic Dysfunction
#323Device and method of monitoring a patient
#324MARKER PANEL FOR LEFT VENTRICULAR HYPERTROPHY
#325Use of mimecan in the assessment of heart failure
#326SCN5A SPLICING FACTORS AND SPLICE VARIANTS FOR USE IN DIAGNOSTIC AND PROGNOSTIC METHODS
#327TREATMENT OF ONCOSTATIN M RECEPTOR BETA MEDIATED HEART FAILURE
#328Methods for Predicting Cardiovascular Mortality Risk
#329Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP
#330Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
#331B-lymphocyte targeting agents for use in a method for the treatment of a disease
#332Bin1 as a Prognostic Marker in Cardiovascular Disease
#333Post-translation modified cardiac troponin T as a biomarker of a risk for heart failure
#334Signal biomarkers
#335Methods of identifying a subject as having heart failure
#336Detection of degradation products of canine NT-proBNP
#337Method of treating renal dysfunction based on perlecan as a biomarker
#338GALECTIN-3 AND STATIN THERAPY
#339METHODS FOR DIAGNOSING KIDNEY DAMAGE ASSOCIATED WITH HEART FAILURE
#340DIAGNOSTIC METHODS USING BNP
#341Antibodies that bind alpha subunit of sodium potassium ATPase
#342Naphthalene-based inhibitors of anti-apoptotic proteins
#343DETECTING AND MONITORING LEFT VENTRICULAR HYPERTROPHY AND CONGESTIVE HEART FAILURE BY PROFILING BIOMARKERS
#344ENDOSTATIN AS A MARKER OF HEART FAILURE
#345DIFFERENTIATING CARDIAC- AND DIABETES MELLITUS-BASED CAUSES OF KIDNEY DAMAGE
#346Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
#347METHOD FOR THE DIAGNOSIS OF AGE-ASSOCIATED VASCULAR DISORDERS
#348METHODS AND COMPOSITIONS FOR DETECTING CANINE DILATED CARDIOMYOPATHY (DCM)
#349Corin As A Marker For Heart Failure
#350BIOMARKERS
#351METHODS AND COMPOSITIONS FOR THE REGULATION OF LECTIN COMPLEMENT PATHWAY (LCP)-ASSOCIATED COMPLEMENT ACTIVATION IN HYPERGLYCEMIC MYOCARDIAL DAMAGE
#352Angiogenin complexes (ANGex) with lipid-based substrates and uses thereof
#353Methods for treatment of cardiovascular disease
#354BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF ACUTE HEART FAILURE AND USES THEREOF
#355Predicting mortality and detecting severe disease
#356Biomarkers of Mineralocorticoid Receptor Activation
#357NOVEL POLYPEPTIDES RELATED TO B-TYPE NATRIURETIC PEPTIDES AND METHODS OF THEIR IDENTIFICATION AND USE
#358IL1RL-1 as a cardiovascular disease marker and therapeutic target
#359LTBP2 AS A BIOMARKER FOR RENAL DYSFUNCTION
#360IMMUNOASSAYS FOR AUTOANTIBODIES IN CARDIOVASCULAR DISEASES
#361Granin proteins as markers of heart disease
#362HUMAN B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS
#363DIAGNOSIS AND TREATMENT OF BACK PAIN
#364Diagnostic methods for congestive heart failure
#365PROTEIN PHOSPHATASE-1 INHIBITOR-1 POLYMORPHISM AND METHODS OF USE
#366Use application of sugar chain-recognizing receptor
#367USE OF BIGLYCAN IN THE ASSESSMENT OF HEART FAILURE
#368Identification of a Gene Expression Profile that Differentiates Ischemic and Nonischemic Cardiomyopathy
#369Blood Glutathione as a Biomarker for Screening Asymptomatic Patients at Risk for Heart Failure
#370Assay for diagnosis of cardiac myocyte damage
#371Methods of predicting and treating adverse cardiac events
#372MULTIMARKER PANEL FOR DIFFERENTIATION OF DILATED CARDIOMYOPATHY AND AS A BASIS FOR DIFFERENTIAL THERAPY
#373Highly sensitive system and method for analysis of troponin
#374MULTIMARKER PANEL FOR MONITORING PATIENTS WITH AND WITHOUT OVERT HEART FAILURE
#375DIAGNOSIS OF EARLY STAGE CARDIAC DYSFUNCTION
#376Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
#377Galectin-3 and cardiac resynchronization therapy
#378Assessing susceptibility to cardiac intervention, susceptibility to therapy for heart failure, risk of mortality or further cardiovascular events, and risk of subsequent pulmonary embolism in relevant patients based on determinations of GDF-15, natriuretic peptide, cardiac troponin or combinations thereof
#379L-FABP, natriuretic peptides, and cardiac troponins in subjects in need of cardiac therapy
#380Future cardiac event biomarkers CCL3, CCL5 and CCL18
#381CACNB2 nucleic acid mutations as indicators of shorter than normal QT interval and ST segment elevation associated with sudden cardiac death
#382ASSESSING CONGESTIVE HEART RISK IN PATIENTS TREATED OR POTENTIALLY TO BE TREATED WITH A PEROXISOME-PROLIFERATOR-ACTIVATOR-RECEPTOR-GAMMA AGONIST OR A THIAZOLIDINEDIONE
#383METHODS FOR DETECTING MAJOR ADVERSE CARDIOVASCULAR AND CEREBROVASCULAR EVENTS
#384Use of SFRP-3 in the assessment of heart failure
#385Markers associated with arteriovascular events and methods of use thereof
#386Highly sensitive biomarker panels
#387DIAGNOSIS AND TREATMENT OF CARDIAC DISORDERS
#388Assay for cardiac troponin autoantibodies
#389GENE TARGETS IN ANTI-AGING THERAPY AND TISSUE REPAIR
#390NOVEL DIAGNOSTIC SENSOR FOR RAPID AND REPRODUCIBLE RO52 PROTEIN DOMAIN DETECTION
#391Diagnostic methods for acute ischemic disease using activated hepcidin as an indicator
#392METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE
#393Highly sensitive system and methods for analysis of troponin
#394Assays
#395Use of SLIM-1 in the assessment of heart failure
#396USE OF IGFBP-7 IN THE ASSESSMENT OF HEART FAILURE
#397Methods and compositions related to arrhythmogenic right ventricular cardiomyopathy (ARVC)
#398Naphthalene-based inhibitors of anti-apoptotic proteins
#399Osteopontin as Novel Prognostic Biomarker for Heart Failure
#400Methods of detection of factor XIa and tissue factor
#401NT-proBNP/troponin ratio for assessing myocardial dysfunction
#402Method for assessing risk of heart failure
#403DIFFERENTIATION OF CAUSES OF RIGHT HEART FAILURE
#404Novel Nucleotide and Amino Acid Sequences, and Assays and Methods of Use Thereof for Diagnosis of Cardiac Disease
#405NATRIURETIC PEPTIDE/GDF-15 RATIO FOR DIAGNOSIS OF CARDIAC DISORDERS
#406NOVEL PEPTIDES
#407Methods of screening a subject for mutations associated with novel X-linked muscular myopathies
#408Methods and Compositions for Detecting and Treating End-Stage Cardiomyopathy Using Claudin-5
#409SELECTIVE INHIBITION OF HISTONE DEACETYLASES 1 AND 2 AS A TREATMENT FOR CARDIAC HYPERTROPHY
#410Methods for the detection and monitoring of congestive heart failure
#411Screening Assays for Antagonists and Analyses of Cardiac Hypertrophy
#412FIBROSIS INHIBITOR
#413Assessing heart failure in patients with atrial fibrillation using GDF-15 and natriuretic peptides
#414IL1RL-1 as a cardiovascular disease marker and therapeutic target
#415Biomarkers for chronic vascular dysfunction
#416PROGNOSIS AND RISK ASSESSMENT IN PATIENTS SUFFERING FROM HEART FAILURE BY DETERMINING THE LEVEL OF ADM AND BNP
#417NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2)
#418Galectin-3 Immunoassay
#419Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for NYHA I patients
#420Method of determining equine NT-proBNP
#421Compositions and methods for inhibiting G protein signaling
#422TRANSCRIPTOMIC BIOMARKERS FOR INDIVIDUAL RISK ASSESSMENT IN NEW ONSET HEART FAILURE
#423DIAGNOSIS AND RISK STRATIFICATION OF CARDIAC INSUFFICIENCY USING NEUROPHYSIN
#424Diagnostic means and methods using troponin T and NT-proBNP
#425METHOD FOR DETECTING DISEASE-ASSOCIATED MUTATIONS
#426Methods for predicting effectiveness of apheresis therapy for heart failure
#427Procalcitonin-based diagnosis of infections or inflammatory diseases of the respiratory tract in a patient with heart failure
#428TIMP-4 AS A BIOMARKER FOR THE DIAGNOSIS OF CARDIAC INSUFFICIENCY
#429Angiogenin complexes (ANGex)
#430Protein activity modification
#431Predicting heart failure following myocardial infarction by protease and protease inhibitor profiling
#432Diagnosis of cardiovascular disease
#433METHOD FOR QUANTITATIVE MEASUREMENT OF CARDIAC BIOCHEMICAL MARKERS
#434POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNP
#435Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
#436Method for controlling the therapy of patients suffering from cardiac insufficiency by means of in vitro determination of threshold values of vasoactive peptides
#437IDENTIFICATION OF A GENE EXPRESSION PROFILE THAT DIFFERENTIATES ISCHEMIC AND NONISCHEMIC CARDIOMYOPATHY
#438Methods and kit for early detection of acute coronary syndrome and prediction of adverse cardiac events
#439Diagnostic test for cardiomyopathy
#440ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES
#441Calcium/Calmodulin-Dependent Protein Kinase Kinase as a Control Point for Cardiac Hypertrophy
#442Animal Model With Induced Arrhythmia
#443Methods for the detection and monitoring of congestive heart failure
#444Detecting diastolic heart failure by protease and protease inhibitor plasma profiling
#445INHIBITION OF EXTRACELLULAR SIGNAL-REGULATED KINASE 1/2 AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE
#446PARAOXONASE 1 ENZYMATIC ACTIVITY, A RISK INDICATOR FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS
#447ALTERED SUMOYLATION OF LAMIN A PROTEIN ASSOCIATED WITH DILATED CARDIOMYOPATHY
#448Methods for diagnosis of cardiovascular disease
#449Peptide for inhibition of calcineurin, nucleic acid, antibody, and diagnostic and therapeutic methods of use
#450Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
#451Human BNP immunospecific antibodies
#452Assays
#453Diagnostic methods for congestive heart failure
#454Methods and Compositions for Measuring Canine BNP and Uses Thereof
#455Device and method of monitoring a patient
#456NT-proANP and NT-proBNP for diagnosing cardiac diseases
#457CARDIOVASCULAR AUTOIMMUNE DISEASE PANEL AND METHODS OF USING SAME
#458Novel GPCR and methods of use of the same
#459METHODS FOR IDENTIFYING AGENTS THAT TARGET LEAKS IN RYANODINE RECEPTORS
#460ASSAY FOR CARDIAC TROPONIN AUTOANTIBODIES
#461RYR2 MUTATIONS
#462HUMAN B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS
#463Methods for assessing the risk for development of cardiovascular disease
#464Highly Sensitive System and Methods for Analysis of Troponin
#465Angiogenin complexes (ANGex) and uses thereof
#466Compositions comprising human brain natriuretic peptide (BNP) fragments
#467Methods for treatment with bucindolol based on genetic targeting
#468Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
#469Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease
#470Apelin and uses thereof
#471Novel brain natriuretic peptide variants and methods of use thereof
#472Human BNP immunospecific antibodies
#473CACNA1C nucleic acid mutations as indicators of shorter than normal QT interval and ST segment elevation associated with sudden cardiac death
#474Assay for cardiac troponin autoantibodies
#475Methods for treatment with bucindolol based on genetic targeting
#476Methods and compositions for treating diastolic dysfunction
#477Biomarker fragments for the detection of human BNP
#478Markers associated with arteriovascular events and methods of use thereof
#479Novel TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC47615, HNMDA-1, TWIK-9, alpha2delta-4, 8099, 46455, 54414, 53763, 97076, 97102, 44181, 67084Fl and 67084alt molecules and uses therefor
#480Diagnostic method for myopathy
#481Isoforms of brain natriuretic peptide
#482Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure
#483ENHANCED MEDICAL TREATMENT IN DIABETIC CARDIOMYOPATHY
#484Cardiac muscle function and manipulation
#485Predicting mortality and detecting severe disease
#486Human G protein-coupled receptor and modulators thereof for the treatment of cardiovascualr disorders
#487Human G protein-coupled receptor and modulators thereof for the treatment of cardiovascular disorders
#488Prognostic Methods for Congestive Heart Failure
#489Identifying susceptibility to cardiac hypertrophy
#490Human BNP immunospecific antibodies
#491Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
#492Urinalysis for the early detection of and recovery from worsening heart failure
#493Methods of determination of activation or inactivation of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems
#494Methods of treating cancer, arthritis and/or diabetes with angiopoietins
#495Cardiac muscle function and manipulation
#496Method for detecting disease-associated mutations
#497Method for diagnosis of heart failure
#498Use of calcium binding proteins to improve cardiac contractile function
#499Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
#500PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies
#501Methods and compositions for therapeutic intervention in cardiac hypertrophy
#502Method of screening remedy for heart disease and medicinal composition for treating heart disease
#503Markers for sudden death in heart failure
#504IL1RL-1 as a cardiovascular disease marker and therapeutic target
#505Cardiac muscle function and manipulation
#506Cardiac muscle function and manipulation
#507Interleukin-13 as a cardiovascular disease marker
#508Diagnosis
#509Methods for treatment with bucindolol based on genetic targeting
#510Methods of identification of biomarkers with mass spectrometry techniques
#511Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease
#512Method of diagnosis and agents useful for same
#513Tissue inhibitor of metalloproteinase (TIMP) as a marker and predictor of cardiovascular disease and both cardiac and non-cardiac mortality
#514Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP
#515Cardiac pressure overload associated genes
#516Methods and compositions for measuring canine BNP and uses thereof
#517Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-1
#518Brain natriuretic peptide spliced variant
#519Method for diagnosing arrhythmogenic right ventricular dysplasia
#520Method for treating myolytic disease and method for screening antimyolytic agent
#521Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by NRG-2
#522Inhibitors of caspase-3-mediated cleavage of essential ventricular myosin light chain
#523Diagnosis and therapy of conditions by detection or modulation of the alms1 gene or protein
#524Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
#525Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
#526Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
#527Identification of a gene expression profile that differentiates ischemic and nonischemic cardiomyopathy
#528Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof
#529Methods for diagnosis of cardiovascular disease
#530Diagnostic methods for congestive heart failure
#531Methods and formulations for diagnosing, monitoring, staging and treating heart failure